Abbott nabs U.K. reimbursement win for FreeStyle Libre CGM

This article was originally published here

Abbott (NYSE:ABT) said today that its FreeStyle Libre continuous glucose monitoring system will be available for reimbursement in the U.K., starting on Nov. 1.

The company’s system is designed to automatically read glucose levels through a sensor that’s worn on the back of a person’s upper arm for up to 14 days, thereby eliminating routine finger sticks.

Get the full story at our sister site, Drug Delivery Business News.

The post Abbott nabs U.K. reimbursement win for FreeStyle Libre CGM appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply